



Request for Quotation (RFQ)

Procurement and Supplying Medicine for 2024 – 97 Health Services Project in Baghlan

Issue Date: 02 July 2025

RFQ# ORCDG/2025/0019

Closing Date: 12 July 2025

RFQ Validity: 60 Days

1. Introduction

ORCD Global Inc. is a U.S. based non-governmental, and not-for-profit founded in 2017. ORCDG was registered in the State of California, United States of America (USA) on 05 November 2017 (Registration No: C4076735). Later, it was registered as an international organization in Afghanistan in December 2018 (Registration number 460).

With funding from Muslim Aid & UMCOR, ORCDG is implementing an integrated Health, WASH & DRR response project in Baghlan province, aimed at provision of basic healthcare services and access to clean water to vulnerable and disaster affected people. The project title is: 2024 - 97 HLC - Provision of Basic Healthcare services through MHT in Baghlan province.

2. Scope of Services

2.1. Location details: ORCDG intends to Purchase Medicine to support the operations of Mobile Health Team(s) for the first quarter of the project. The medicine will be used across Baghlan province. Please see below the location details:

Province	Delivery Address	Delivery Date
Baghlan	Pol-e- Khomri	To be decided

2.2. Bill of Quantity for medicine:

Companies interested in participating must complete the Bill of Quantities below by offering unit and total prices for each item. Firms are requested to cross-check their pricing and be accurate in providing the total price.

All vendors are cordially requested to fill out the table and propose medicine from multinational, reputable companies with high-quality products as the main objective of this project is to provide the most vulnerable communities with high-quality services which includes providing them with good quality medications.



مؤسسه پژوهش علمی و توسعه جامعه-گلوبل Organization for Research & Community Development Global

S N	Item Description	Specification/ Unit	Company	Country	CoPP	G M P	Quality Control	Qty	Unit rate (USD)	Total Price (USD)	Remarks
1	Oxygen	Inhalation (medical gas)						1			
2	Lidocaine hydrochloride,	solution for injection, 10 mg/ml (1%), 20-ml ampoule						4			
3	Lidocaine + Adrenaline	injection solution 1% + epinephrine 1:200,000 in vial						4			
4	Paracetamol (acetaminophen)	Tablet 500 mg						7000			
5	Paracetamol (acetaminophen)	Syrup 120 mg/5 ml						450			
6	Paracetamol (acetaminophen)	Tablet 100 mg						4000			
7	Acetyl Salicylic Acid	Tablet 500 mg						3000			
8	Ibuprofen	Tablet 200 mg						3500			
9	Diclofenac	injection 25mg per ml in 3 ml ampoule						100			
10	Diazepam (anxiolytic)	injection 5 mg/ml in 2-ml ampoule						50			
11	Magnesium Sulfate	injection 500 mg/ml in 20-ml ampoule						50			
12	Phenobarbital	Tablet 15 mg						400			
13	Phenobarbital (Antiepileptic for children)	Tablet 100 mg						400			
14	Activated charcoal	Tablet 500 mg						50			
15	Neostigmine	injection 0.5 mg/ml						10			

16	Chlorpheniramine Maleate (Chlorpheniramine)	Tablet 4 mg						3000			
17	Chlorpheniramine Maleate (Chlorpheniramine)	injection 10 mg/ml in 1-ml ampoule						30			
18	Mebendazole	chewable tablet 100 mg						4000			
19	Albendazole	400mg chewable tablets/PAC-100						1200			
20	Amoxicillin	capsules/tablet 500 mg (anhydrous)						4000			
21	Amoxicillin	capsules/tablet 250 mg (anhydrous)						3000			
22	Amoxicillin	powder for oral suspension 125 mg/5 ml (anhydrous)						260			
23	Ampicillin	powder for injection 1g (as sodium salt)						150			
24	Ampicillin	powder for injection 500 mg (as sodium salt)						200			
25	Azithromycin,	capsule, 250 mg						2000			
26	Azithromycin,	suspension, 200mg/5ml, bottle 15 ml						400			
27	Cloxacillin	Capsule 500 mg						1000			
28	Cefixime,	tablet, 200 mg						800			
29	Cefixime (as trihydrate),	dry syrup for oral suspension, 100mg/5ml, bottle 30ml						100			
30	Phenoxymethyl	Tablet 250 mg (as potassium-salt)						2000			



	Penicillin (Penicillin V)										
31	Phenoxy Methyl Penicillin (Penicillin V)	powder for oral suspension 250 mg/5 ml (as potassium salt)						200			
32	Erythromycin (Ethyl succinate)	Suspension 100 mg per ml 100 ml bottles						250			
33	Doxycycline	capsule/tablet 100 mg (hydrochloride)						4000			
34	Gentamicin	injection 10 mg (as sulfate)/ml in 2-ml vial						200			
35	Gentamicin	injection 40 mg (as sulfate)/ml in 2-ml vial						200			
36	Gentian Violet (Methyl Rosanilinium Chloride)	aqueous solution 1% (or crystals)						60			
37	Silver Sulfadiazine	Cream 1%						10			
38	Chlorhexidi ne	gel 7.1%						30			
39	Chlorhexidi ne gluconate,	concentrated solution, 5%, bottle, 1000 ml						6			
40	Povidone Iodine	Solution 10% 450ML						6			
41	Co- trimoxazole (Sulfamethox azole + Trimethopri m)	Tablet 100 mg + 20 mg						5000			
42	Co- trimoxazole (Sulfamethox azole + Trimethopri m)	Tablet 400 mg + 80 mg						3500			

43	Co-trimoxazole (Sulfamethoxazole + Trimethoprim)	suspension 200 mg + 40 mg/5 ml						150			
44	Metronidazole	Tablet 250 mg, 200mg						1000			
45	Metronidazole	Tablet 400 mg, 500mg						2000			
46	Metronidazole	oral suspension 200 mg (as benzoate)/5 ml						400			
47	Nystatin	coated tablet 100,000 IU						1500			
48	Nystatin	coated tablet 500,000 IU						200			
49	Clotrimazole,	vaginal tablet, 500 mg						200			
50	Lindane	lotion 1%						80			
51	Chloroquine	Tablet 150 mg (as phosphate or sulfate)						200			
52	Artemether + lumefantrine	Tablet 20mg + 120mg						150			
53	Artemether + lumefantrine	Tablet 80mg + 480mg						200			
54	Adrenaline	injection 1 mg (as hydrochloride or hydrogen tartrate) in 1-ml ampoule						10			
55	Ferrous Sulfate	Tablet equivalent to 60 mg iron						15000			
56	Ferrous Sulfate	oral solution equivalent 25 mg iron (as sulfate)/ml						200			
57	Ferrous Sulfate + Folic Acid	Tablet equivalent to 60 mg iron + 400 mcg folic acid						10000			
58	Folic Acid	Tablet 5 mg						10000			

59	Atenolol	Tablet 50 mg						500			
60	Methyl Dopa	Tablet 250 mg						500			
61	Glyceryl trinitrate	Tablet 0.5 mg, sublingual						1000			
62	Acetyl salicylic acid (Acetylsalicylic Acid)	Tablet 100 mg						4000			
63	Aluminum Hydroxide	tablet 500 mg						4000			
64	Aluminum Hydroxide + Magnesium Hydroxide	chewable tablet aluminum hydroxide 200 mg + magnesium hydroxide 200 mg						4000			
65	Aluminum Hydroxide + Magnesium Hydroxide	suspension aluminum hydroxide 225 mg + magnesium hydroxide 200 mg/5 ml						300			
66	Metoclopramide	tablet 10 mg (hydrochloride)						1000			
67	Metoclopramide	injection 5 mg (hydrochloride)/ml in 2-ml ampoule						200			
68	Low Osmolality ORS 20.5gr/liter	Glucose anhydrous 13.5g, Sodium chloride 2.6g, Trisodium citrate dehydrate 2.9 gm, Potassium chloride 1.5g for one liter						4000			
69	Hydrocortisone	powder for injection 100 mg (as sodium succinate) in vial						150			
70	Betamethasone + Neomycin	Cream 1% + 0.5 %						150			



71	Tetracycline	eye ointment 1% hydrochloride 5 gr						150			
72	Aminophylline	tablet 100 mg						2500			
73	Salbutamol	tablet 4 mg						2500			
74	Salbutamol	inhalation (aerosol) 100 microgram (as sulfate) per dose						150			
75	Salbutamol	syrup 2 mg (as sulfate)/5 ml						150			
76	Prednisolone	Tablet 5 mg						400			
77	Male condoms							3000			
78	Ethinylestradiol, 0.03 mg, plus levonorgestrel, 0.15 mg,	combined tablet I strip for 1 cycle (56 women x 3 cycles + 10% wastage)						1500			
79	Levonorgestrel,	tablet, 0.03 mg, 1 strip for 1 cycle (10 women x 3 cycles)						1000			
80	Medroxyprogesterone acetate, depot	injection, 150 mg/ml, 1-ml vial						400			
81	Oxytocin, injection, 10 IU/ml, 1-ml ampoule	10 IU/ml, 1-ml ampoule						400			
82	Fluoxetine	Capsule 20mg						2500			
83	Diazepam	Tablet 5mg, 10mg						2500			
84	Phenobarbital	Tablet 15mg, 100mg						2500			
85	Carbamazepine	Tablet 200mg						2500			

86	Sodium Chloride	injectable solution 0.9% isotonic (equivalent to Na ⁺ 154mmol/l, Cl ⁻ 154 mmol/l) 1-litre bottle + infusion giving set, sterile, single use						250			
87	Compound solution of Sodium Lactate	injectable solution						250			
88	Glucose	injectable solution 10% isotonic 5% isotonic						250			
89	Glucose with Sodium Chloride	injectable solution 4% glucose, 0.18% NaCl (equivalent to Na ⁺ , 30 mmol/l, Cl ⁻ , 30 mmol/l)						170			
90	Water for injection	5 ml						2002			
91	Water for injection	10 ml						1322			
92	Hydrochlorot hiazide	tablet 50mg						1503			
93	Vitamin A	100,000 IU, soft gel caps/PAC 500						3000			
94	Vitamin A	200,000 IU, soft gel caps/PAC 500						1500			
95	Zinc	Zinc Dispersible Tablet 20mg strip of ten						3000			
96	Vitamin K	Injection 10mg per ml ampoule						2500			



3. Short listing and evaluation

The bidding process for the above mentioned services will be conducted in two stages. In stage one, a bid opening ceremony will be held in presence of the representatives from all vendors. During the bid opening phase, the offers of vendors will be opened and their prices will be openly announced.

The first Evaluation Stage contains the following:

(To be decided and filled by ORCDG)

First Evaluation (Prequalification stage) Stage			
SN	Pass/Fail Criteria	Pass	Fail
1	Submission of a valid business license, registered with the Ministry of Commerce/other relevant government department		
2	Submission of previous experience supporting documents including copies of medicine supply contract for humanitarian projects (INGOs or UN). Up to three copies of contracts should be provided.		
3	Providing a list of contacts for 5 references (individuals) from previous clients (including INGOs and UN). ORCDG may confirm the satisfaction of previous clients through email during the 2 nd stage.		
4	Bid properly sealed with all technical and financial bids submitted without correction in a sealed envelope with contact number & Company Official Email address clearly written on top of the envelope		
5	All submitted bid documents including supporting documents and annexures properly completed, signed, and stamped.		
6	Financial Bids provided in ORCDG RFQ template only		
7	A bid security amount of up to USD 500 provided (through an official letter from one of the legal banks in Afghanistan)		
If a vendor fails to meet any of the above criterion, their bid will be eliminated, and the bidder will be disqualified from the process.			

The 2nd stage of evaluation will be performed by an internal and independent committee assigned by the ORCDG management. The committee will review the specifications, prices and supporting documents of vendors. Furthermore, the committee may request the top three vendors to provide samples of medicine to ensure that drugs meet all quality standards. The purpose of the 2nd stage is to ensure that the medications ORCDG will be providing through its intervention meet international quality standards and



are purchased/imported from multinational, reputable companies. **ORCDG's internal committee reserves the right to reject samples provided by companies if found undesirable.**

4. Confidentiality and Conflicts of Interest

- ✓ It is a further condition of proposing that you will keep confidential the information disclosed to you in this invitation to proposal and in connection with the invitation and your response to the invitation. You must also return to ORCDG any information disclosed (and any copies you have made of this) if requested and must only use such information for the purposes of making the proposal.
- ✓ In the same manner, any information received relating to the proposing company will be treated in the strictest of confidence by the ORCDG.
- ✓ A company will not be eligible for appointment if any of its partners, directors or major shareholders is a member of the ORCDG Board or the staff of ORCDG.
- ✓ Companies must declare, as part of the proposal, whether any partners, directors, major shareholders, senior staff, or the partners / spouses of any of these listed are:
 - Members of ORCDG Board or related to any such member.
 - An employee of ORCDG or related to any such employee.
- ✓ Companies should also identify any work they are currently undertaking, or bidding for, which could cause a conflict of interest, and indicate how they will deal with this potential conflict if the contract is awarded.

5. Form of proposal – information to be provided.

To be considered, your proposal submission must include the following information. Failure to supply such information, in the requested format where specified, will result in your proposal not being considered.

5.1. The RFQ will be evaluated using the following technical criteria. Proposals should address each question.

1. Does the company have a valid license? If yes, please provide us the scan copies.
2. Does the company have a quality control program to help ensure adherence to high professional standards?
3. Does the proposal fully respond to the needs of ORCDG about this Medicine supply?
4. Will the company be able to meet ORCDG deadline? Does the number of days or the time period indicated by the company to complete the related tasks?
5. Has the company had the same experience with other NGOs or institutions? If so, please list the NGOs/institutions and indicate if we may contact them.
6. Does the proposal adequately describe in a clear concise, and understandable manner the work to be performed including sampling techniques and analytical procedures to be used?



5.2. Information about your company:

- a. A short profile of your company with emphasis on the different services you supply. If the company is part of a group of companies, or is a subsidiary or parent company, please also give details of the group.

5.3. Experience:

- a. Details of your firm's experience of providing similar services, and in particular experience of working with similar organization's funded projects in Afghanistan.

5.4. Costs:

- a. All cost shall be inclusive of all applicable taxes as per taxation law of the government of Afghanistan, www.mof.af, TA/DA.
- b. The quotation price should be given in **USD**.

5.5. Payment:

- a. Once the contract is signed with a company and complete the supply, all the payment will be processed through bank transfer after receiving fund from donor, the company is not supposed to request ORCDG for cash or cheque payment.
- b. Additionally, the payment will be processed to the partner company's bank account not individual bank account.

6. Submission Procedure

- ✓ Please submit the one hard sealed stamp copy of RFQ and send it to ORCDG Office House# 28, Street of Shams London Academy Girls School, Shaheed Square, Taimani Project Kabul, Afghanistan by **02:00 PM (AFT), 12 July 2025** or before the deadline.
- ✓ Should you have any questions until closing date, please feel free to contact us via tender@orcdglobal.org
- ✓ No proposal will be considered if received after the deadline set out above.

7. Disclaimer

ORCDG is not bound contractually or in any other way to any Proponent to this request for proposal/bid. The organization is not liable for any costs or compensation in relation to the consideration of this Request for submission of proposal/bids by the Proponents whether or not



the organization terminates, varies, or suspends the process or takes any other action permitted under this Request for proposals/bids.

The organization may, at its absolute discretion, elect to abandon any part or whole of the process without giving prior notice to the Proponents or potential Proponents.

Sincerely,

Procurement & Logistic Department
ORCDG Afghanistan